GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Invictus MD Strategies Corp (OTCPK:IVITF) » Definitions » Beta

Invictus MD Strategies (Invictus MD Strategies) Beta : -53.65 (As of Apr. 27, 2024)


View and export this data going back to 2015. Start your Free Trial

What is Invictus MD Strategies Beta?

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2024-04-27), Invictus MD Strategies's Beta is -53.65.


Invictus MD Strategies Beta Historical Data

The historical data trend for Invictus MD Strategies's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Invictus MD Strategies Beta Chart

Invictus MD Strategies Annual Data
Trend Jan15 Jan16 Jan17 Jan18 Jan19
Beta
- - - - 4.35

Invictus MD Strategies Quarterly Data
Jan15 Apr15 Jul15 Oct15 Jan16 Apr16 Jul16 Oct16 Jan17 Apr17 Jul17 Oct17 Jan18 Apr18 Jul18 Oct18 Jan19 Apr19 Jul19 Oct19
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.63 4.35 3.12 2.76 3.84

Competitive Comparison of Invictus MD Strategies's Beta

For the Drug Manufacturers - Specialty & Generic subindustry, Invictus MD Strategies's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Invictus MD Strategies's Beta Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Invictus MD Strategies's Beta distribution charts can be found below:

* The bar in red indicates where Invictus MD Strategies's Beta falls into.



Invictus MD Strategies Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.


Invictus MD Strategies  (OTCPK:IVITF) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)


Invictus MD Strategies Beta Related Terms

Thank you for viewing the detailed overview of Invictus MD Strategies's Beta provided by GuruFocus.com. Please click on the following links to see related term pages.


Invictus MD Strategies (Invictus MD Strategies) Business Description

Traded in Other Exchanges
N/A
Address
595 Burrard Street, 16th floor, Vancouver, BC, CAN, V7X 1J1
Invictus MD Strategies Corp is a cannabis company with a focus on the Canadian cannabis space, offering a selection of products under a wide range of cannabinoid profiles that fit the demand of the company's medical clients and retail customers. Its wholly-owned subsidiary's Phase I and Phase II facilities are in full production. The company's 50% owned subsidiary has completed its Phase II expansion and received its amended license from Health Canada. Another of its wholly owned subsidiary, connects medical clients to physicians for medical cannabis.

Invictus MD Strategies (Invictus MD Strategies) Headlines

From GuruFocus

INVICTUS ANNOUNCES CHANGE TO BOARD

By GlobeNewswire GlobeNewswire 12-13-2019

INVICTUS ANNOUNCES AB LABORATORIES INC. UPDATE

By Marketwired Marketwired 06-26-2019

Invictus announces Closing of Non-Brokered Private Placement

By Marketwired Marketwired 07-09-2019

INVICTUS ANNOUNCES $5,700,000 CONVERTIBLE DEBENTURE FINANCING

By Marketwired Marketwired 12-16-2019

INVICTUS ANNOUNCES AB LABORATORIES INC. RECEIVES AMENDED LICENSE

By Marketwired Marketwired 09-11-2019